2/28/2019 4:05:58 PM
PTC Therapeutics Q4 Loss/share $0.96 Vs. Profit $0.03 Year Ago
1/23/2019 8:56:31 AM
PTC Therapeutics Prices Public Offering Of 6.72 Mln Shares At $30.20/Shr
1/7/2019 8:26:10 AM
PTC Outlines 5-yrs Plan; Multiple Products To Be Launched By 2023 Potentially Generating $1.5 Bln Revenue Annually
1/7/2019 8:23:05 AM
PTC Therapeutics Promotes Mark Pykett To Chief Scientific Officer, Neil Almstead To Chief Technical Operations Officer
10/6/2018 8:05:32 AM
PTC Therapeutics Announces Initial Data From Patient Registry Demonstrating Translarna
10/3/2018 7:38:31 AM
PTC : Risdiplam Shows Preliminary Evidence Of Clinical Benefit In Type 1, 2, & 3 Spinal Muscular Atrophy Patients
8/2/2018 8:12:24 AM
Akcea Therapeutics And PTC Therapeutics Collaborate To Commercialize Two Rare Disease Drugs In Latin America
7/19/2018 4:11:05 PM
PTC Therapeutics To Acquire Agilis Biotherapeutics
4/24/2018 8:56:08 PM
PTC Therapeutics : Preliminary Clinical Data From FIREFISH Trial In Type 1 SMA Patients Presented
4/4/2018 8:08:25 AM
PTC Therapeutics, CHDI Foundation To Collaborate On Small-Molecule Therapeutic For Huntington's Disease
3/28/2018 9:23:17 PM
PTC Therapeutics Prices Public Offering Of 4 Mln Shares At $27.04/share